personal scheduler Hamburg 2013 - Main Site Press Release 2013 Call for Abstracts General Information Programme Overview Letter from the President Keynote Lectures Main Sessions NEW - Free Paper Session Instructional Courses World Retina Day Retinal Detachment Course Uveitis Course Other Symposia Surgical Skills Training Courses
hamburg banner

Comparison of effectiveness of 4 mg and 20 mg intravitreal triamcinolone injections in bilateral diffuse diabetic macular oedema

Session Details

Session Title: Quick Fire Free Paper Session 02

Session Date/Time: Thursday 26/09/2013 | 14:30-16:00

Paper Time: 14:55

Venue: Hall G1 (Level 2)

First Author: B.Kaderli TURKEY

Co Author(s):    R. Avci   A. Yucel   O. Yalcinbayir   O. Gelisken     

Abstract Details

Purpose:

To compare the efficacy of 4 mg and 20 mg intravitreal triamcinolone (IVTA) injections in the treatment of bilateral diabetic diffuse macular oedema (DDMO).

Setting:

Prospective, randomised study

Methods:

Twenty-two eyes of 11 diabetic patients with bilateral DDMO were randomised to receive 4 mg or 20 mg IVTA. Patients were followed up for 6-12 months, and changes in best-corrected visual acuity (BCVA), central foveal thickness (CFT) in optical coherence tomography, side effects and duration of visibility of triamcinolone particles in the vitreous were compared between the two groups

Results:

Both groups had visual improvement and macular edema reduction at 1,3 and 6 months following the injections (p<0.05 for all). Central foveal thickness tended to be lower in the 20 mg group at 9 and 12 months, but the difference failed to reach significance. At 9 and 12 months, the number of eyes with CFT less than 300 µm were 6 (55%) and 2 (18%) in the 4 mg group and 8 (73%) and 5 (45%) in the 20 mg group. Intraocular pressure increased significantly at 1 and 3 months in both groups (p<0.05). Ocular hypertensive response of ≥ 5 mmHg was seen in 4 eyes (36%) and 6 eyes (55%) in the 4 and 20 mg group, respectively. The mean duration of visibility of triamcinolone particles in the vitreous was 3.8 and 7.8 months in the 4 and 20 mg group, respectively. One eye in the 4 mg and 3 eyes in the 20 mg group developed significant cataract during follow-up

Conclusions:

Both doses of IVTA provide anatomical and functional improvement in DDMO during the first 6 post-injection months. However, 20 mg seems to have longer effect and higher rate of complications

Back to Freepaper Session
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy